When to Suspect Secondary Hypertension

  • Donald G. Vidt
Part of the Current Clinical Practice book series (CCP)


A thorough history and physical examination together with selected, office-based laboratory studies are recommended in the evaluation of each new patient with hypertension (Table 13-1). This initial evaluation is designed to assess the presence or absence of target organ damage and cardiovascular disease, to identify other cardiovascular risk factors or comorbid conditions that may have an impact on the prognosis and selection of therapy, and to provide valuable clues to other secondary causes of hypertension. When preliminary examination affords no clues, an extensive search for secondary and possibly curable causes of hypertension is unproductive, unnecessarily costly, and, on occasion, may be hazardous. This chapter does not address the problem of alcohol excess, which represents the most common cause of reversible hypertension in our society, or oral contraceptive therapy, which may be associated with significant hypertension in a small number of women. Table 13-2 summarizes the information to be gained from the initial clinical evaluation regarding selected secondary causes of hypertension, and this information is discussed further in this chapter.


Multiple Endocrine Neoplasia Primary Aldosteronism Resistant Hypertension Renovascular Hypertension Mandelic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Serfas D, Borow KM (1983) Coarctation of the aorta: anatomy, pathophysiology, and natural history. J Cardiovasc Med 8: 575.Google Scholar
  2. 2.
    Kaye TB, Crapo L (1990) The Cushing syndrome: an update on diagnostic tests. Ann Intern Med 112: 434–444.PubMedGoogle Scholar
  3. 3.
    Manger WM, Gifford RW Jr (1977) Pheochromocytoma. New York: Springer-Verlag.CrossRefGoogle Scholar
  4. 4.
    Bravo EL (1991) Pheochromocytoma: new concepts and future trends. Kidney Int 40: 544–556 (clinical conference).Google Scholar
  5. 5.
    Melby JC (1991) Diagnosis of hyperaldosteronism. Endocrinol Metab Clin North Am 20: 247–255.PubMedGoogle Scholar
  6. 6.
    Mann SJ, Pickering TG (1992) Detection of renovascular hypertension. State of the Art: 1992. Ann Intern Med 117: 845–853.PubMedGoogle Scholar
  7. 7.
    National High Blood Pressure Education Program (NHBPEP) Working Group (1996) 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 156: 1938–1947.Google Scholar
  8. 8.
    Moore MA (1993) Renal parenchymal disease: evaluation. In: Izzo JL, Black HR, eds. Hypertension Primer, 3rd ed., Dallas: American Heart Association, pp. 265–267.Google Scholar
  9. 9.
    Streeten DH, Anderson GH Jr, Howland T, Chiang R, Smulyan H (1988) Effects of thyroid function on blood pressure: recognition of hypothyroid hypertension. Hypertension 11:78–83.Google Scholar
  10. 10.
    Richards AM, Espiner EA, Nicholls MG, Ikram H, Hamilton EJ, Maslowski TA (1988) Hormone, calcium and blood pressure relationships in primary hyperparathyroidism. J Hypertens 6:747–752. (published erratum appears in J Hypertens 1988; 6 (11):ii).Google Scholar
  11. 11.
    Joint National Committee (1997) The sixth report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 157: 2413–2446.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Donald G. Vidt

There are no affiliations available

Personalised recommendations